This site is intended for healthcare professionals
Drug news

Cariprazine filed at EMA for treatment of schizophrenia.- Gedeon Richter

Read time: 1 mins
Last updated:12th Apr 2016
Published:12th Apr 2016
Source: Pharmawand

Gedeon Richter Plc. announced that the European Medicines Agency (EMA) has accepted Richter's regulatory submission for cariprazine, a novel antipsychotic for the treatment of schizophrenia in adult patients. Cariprazine was discovered by Richter scientists and is licensed to Allergan (earlier Forest / Actavis), in the U.S. and Canada. Following its FDA approval in September 2015, the product has been recently launched in the USA under the trademark of Vrayler for the treatment of both schizophrenia and bipolar mania.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.